Jan Stahlberg Purchases 240,352 Shares of DiaMedica Therapeutics (NASDAQ:DMAC) Stock

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) major shareholder Jan Stahlberg acquired 240,352 shares of the company’s stock in a transaction that occurred on Wednesday, November 19th. The shares were acquired at an average cost of $7.21 per share, with a total value of $1,732,937.92. Following the purchase, the insider owned 8,375,092 shares in the company, valued at $60,384,413.32. This represents a 2.95% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Jan Stahlberg also recently made the following trade(s):

• On Tuesday, November 25th, Jan Stahlberg bought 73,099 shares of DiaMedica Therapeutics stock. The stock was acquired at an average cost of $8.57 per share, for a total transaction of $626,458.43.
• On Monday, November 24th, Jan Stahlberg bought 40,253 shares of DiaMedica Therapeutics stock. The shares were bought at an average price of $7.89 per share, for a total transaction of $317,596.17.
• On Friday, November 21st, Jan Stahlberg purchased 208,872 shares of DiaMedica Therapeutics stock. The stock was bought at an average price of $7.41 per share, with a total value of $1,547,741.52.
• On Thursday, November 20th, Jan Stahlberg purchased 128,426 shares of DiaMedica Therapeutics stock. The stock was bought at an average cost of $7.41 per share, with a total value of $951,636.66.
• On Tuesday, November 18th, Jan Stahlberg acquired 182,882 shares of DiaMedica Therapeutics stock. The shares were bought at an average cost of $6.75 per share, for a total transaction of $1,234,453.50.
• On Monday, November 17th, Jan Stahlberg bought 187,393 shares of DiaMedica Therapeutics stock. The stock was bought at an average price of $6.52 per share, with a total value of $1,221,802.36.

DiaMedica Therapeutics Stock Up 3.5%

Shares of DMAC opened at $9.07 on Wednesday. DiaMedica Therapeutics, Inc. has a 52-week low of $3.19 and a 52-week high of $9.35. The company has a market capitalization of $472.37 million, a PE ratio of -12.77 and a beta of 1.31. The stock has a fifty day simple moving average of $7.20 and a two-hundred day simple moving average of $5.76.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). As a group, equities analysts anticipate that DiaMedica Therapeutics, Inc. will post -0.59 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on DMAC shares. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of DiaMedica Therapeutics in a research note on Friday, August 15th. Cantor Fitzgerald began coverage on DiaMedica Therapeutics in a research report on Friday, November 14th. They issued an “overweight” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Wednesday, October 8th. TD Cowen began coverage on DiaMedica Therapeutics in a report on Thursday, October 30th. They set a “buy” rating for the company. Finally, Cowen assumed coverage on DiaMedica Therapeutics in a report on Thursday, October 30th. They set a “buy” rating for the company. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $12.33.

Hedge Funds Weigh In On DiaMedica Therapeutics

Several hedge funds have recently bought and sold shares of DMAC. Cooperman Leon G boosted its holdings in DiaMedica Therapeutics by 98.2% during the 3rd quarter. Cooperman Leon G now owns 3,269,761 shares of the company’s stock valued at $22,463,000 after acquiring an additional 1,619,761 shares during the period. Millennium Management LLC purchased a new stake in DiaMedica Therapeutics during the third quarter worth about $8,157,000. Geode Capital Management LLC lifted its position in shares of DiaMedica Therapeutics by 99.6% during the second quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock worth $2,458,000 after purchasing an additional 314,407 shares in the last quarter. Paragon Associates & Paragon Associates II Joint Venture boosted its stake in shares of DiaMedica Therapeutics by 34.6% in the third quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 875,000 shares of the company’s stock valued at $6,011,000 after purchasing an additional 225,000 shares during the period. Finally, Royal Bank of Canada boosted its stake in shares of DiaMedica Therapeutics by 46,879.1% in the first quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock valued at $588,000 after purchasing an additional 154,701 shares during the period. Institutional investors and hedge funds own 10.12% of the company’s stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.